Current Report Filing (8-k)
May 26 2016 - 4:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 23, 2016
ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36172
|
|
22-3106987
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
26 Landsdowne Street, Cambridge, Massachusetts
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617) 494-0400
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(b)
On May 24, 2016, ARIAD
Pharmaceuticals, Inc. (ARIAD or the Company) announced the appointment of Jennifer L. Herron as the Companys Executive Vice President, Chief Commercial Officer, effective May 31, 2016 (the Effective
Date). Ms. Herron will succeed Martin J. Duvall, who will be stepping down as the Companys Chief Commercial Officer as of the Effective Date but will remain with the Company to ensure a seamless transition. A copy of the press
release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
ITEM 9.01
|
Financial Statements and Exhibits.
|
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Press release dated May 24, 2016
|
The press release may contain hypertext links to information on our websites. The information on our websites is not
incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ARIAD Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Manmeet S. Soni
|
|
|
|
|
|
|
Manmeet S. Soni
|
|
|
|
|
|
|
Executive Vice President, Chief Financial Officer
|
Date: May 26, 2016
Exhibit List
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Press release dated May 24, 2016
|
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Apr 2023 to Apr 2024